Total Valuation
YUNGJIN PHARM. CO. LTD has a market cap or net worth of ₩215.63B. The enterprise value is ―.
Market Cap₩215.63B
Enterprise Value―
Share Statistics
YUNGJIN PHARM. CO. LTD has 182,892,730 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding182,892,730
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
YUNGJIN PHARM. CO. LTD’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is 1.64%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)1.64%
Return on Capital Employed (ROCE)0.02
Revenue Per Employee406.16M
Profits Per Employee-363.68K
Employee Count626
Asset Turnover0.97
Inventory Turnover2.70
Valuation Ratios
The current PE Ratio of YUNGJIN PHARM. CO. LTD is ―. YUNGJIN PHARM. CO. LTD’s PEG ratio is 13.62.
PE Ratio―
PS Ratio1.53
PB Ratio4.25
Price to Fair Value4.25
Price to FCF-413.90
Price to Operating Cash Flow-22.87
PEG Ratio13.62
Income Statement
In the last 12 months, YUNGJIN PHARM. CO. LTD had revenue of 254.26B and earned -227.66M in profits. Earnings per share was -1.24.
Revenue254.26B
Gross Profit75.86B
Operating Income3.42B
Pretax Income-212.00M
Net Income-227.66M
EBITDA12.20B
Earnings Per Share (EPS)-1.24
Cash Flow
In the last 12 months, operating cash flow was -9.43B and capital expenditures -9.83B, giving a free cash flow of -19.25B billion.
Operating Cash Flow-9.43B
Free Cash Flow-19.25B
Free Cash Flow per Share-105.27
Dividends & Yields
YUNGJIN PHARM. CO. LTD pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.15
52-Week Price Change-46.53%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)287.57K
Important Dates
YUNGJIN PHARM. CO. LTD upcoming earnings date is Aug 18, 2026, TBA (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 18, 2026
Ex-Dividend Date―
Financial Position
YUNGJIN PHARM. CO. LTD as a current ratio of 1.48, with Debt / Equity ratio of 95.88%
Current Ratio1.48
Quick Ratio0.81
Debt to Market Cap0.24
Net Debt to EBITDA5.37
Interest Coverage Ratio0.82
Taxes
In the past 12 months, YUNGJIN PHARM. CO. LTD has paid 15.66M in taxes.
Income Tax15.66M
Effective Tax Rate-0.07
Enterprise Valuation
YUNGJIN PHARM. CO. LTD EV to EBITDA ratio is 37.26, with an EV/FCF ratio of -483.66.
EV to Sales1.79
EV to EBITDA37.26
EV to Free Cash Flow-483.66
EV to Operating Cash Flow44.38
Balance Sheet
YUNGJIN PHARM. CO. LTD has ₩6.27B in cash and marketable securities with ₩85.15B in debt, giving a net cash position of -₩78.88B billion.
Cash & Marketable Securities₩6.27B
Total Debt₩85.15B
Net Cash-₩78.88B
Net Cash Per Share-₩431.30
Tangible Book Value Per Share₩461.03
Margins
Gross margin is 29.07%, with operating margin of 1.34%, and net profit margin of -0.09%.
Gross Margin29.07%
Operating Margin1.34%
Pretax Margin-0.08%
Net Profit Margin-0.09%
EBITDA Margin4.80%
EBIT Margin1.34%
Analyst Forecast
The average price target for YUNGJIN PHARM. CO. LTD is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast1.10%
EPS Growth Forecast-85.07%